BRU · UCB.BR
UCB S.A.
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
Loading market information…
BRU · HYL.BR · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 03:41 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Hyloris Pharmaceuticals S.A.’s quoted price sits in the lower half of its reported 52-week range, 54.05% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Hyloris Pharmaceuticals S.A.’s next earnings report is currently expected on Mar 17, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Hyloris Pharmaceuticals S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Hyloris Pharmaceuticals SA is dedicated to developing, manufacturing, and bringing to market pharmaceutical products designed to fulfill critical unmet medical needs. The company's focus areas include cardiovascular health, oncology, women's health, and other significant therapeutic domains. Its cardiovascular portfolio features treatments for conditions such as atrial fibrillation, acute coronary syndrome, advanced and congestive heart failure, and coronary heart disease. Beyond this, Hyloris addresses a diverse range of other ailments, including post-operative pain management, dental indications, severe and recurring vulvovaginal candidiasis, specific cancers (like acute myeloid leukemia and small cell lung cancer), interstitial cystitis/painful bladder syndrome (IC/PBS), attention deficit hyperactivity disorder (ADHD), and various viral infections. Established in 2012, Hyloris Pharmaceuticals SA is headquartered in Liège, Belgium.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:18 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
€227.60+€6.80 (+3.08%)
Financière de Tubize S.A.’s quoted price sits in the upper half of its reported 52-week range, 9.14% below the high.
€16.46+€0.12 (+0.73%)
Ion Beam Applications S.A.’s quoted price sits in the upper half of its reported 52-week range, 7.32% below the high.
€2.23-€0.03 (-1.11%)
Onward Medical N.V.’s quoted price sits in the lower half of its reported 52-week range, 61.35% below the high.
€0.61€0.00 (0.0%)
Sequana Medical N.V.’s quoted price sits in the lower half of its reported 52-week range, 62.24% below the high.
€3.60-€0.36 (-9.09%)
European Medical Solutions’s quoted price sits in the lower half of its reported 52-week range, 34.55% below the high.
€0.21€0.00 (0.0%)
Celyad Oncology S.A.’s quoted price sits in the lower half of its reported 52-week range, 67.69% below the high.
€0.00€0.00 (0.0%)
BioSenic S.A.’s quoted price sits in the lower half of its reported 52-week range, 28.57% below the high.
